PRECISION OPTICS CORPORATION, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PRECISION OPTICS CORPORATION, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $19.09M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $19.10M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $21.04M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $15.68M | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | $10.67M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $9.92M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $6.80M | Sep 24, 2020 |
| FY2019 | Jun 30, 2018 | $4.04M | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | $3.15M | Sep 27, 2018 |
| FY2017 | Jun 30, 2016 | $3.92M | Sep 28, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.40M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $5.80M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $7.73M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $4.93M | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | $3.43M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $3.36M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $2.12M | Sep 24, 2020 |
| FY2019 | Jun 30, 2018 | $1.48M | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | $773.7K | Sep 27, 2018 |
| FY2017 | Jun 30, 2016 | $942.0K | Sep 28, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($5.78M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($2.95M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($144.6K) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($928.4K) | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | ($102.8K) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($1.43M) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($614.9K) | Sep 24, 2020 |
| FY2019 | Jun 30, 2018 | ($351.4K) | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | ($1.01M) | Sep 27, 2018 |
| FY2017 | Jun 30, 2016 | ($1.03M) | Sep 28, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($5.55M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($2.72M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($638.5K) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($1.51M) | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | ($905.6K) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($1.42M) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($612.5K) | Sep 24, 2020 |
| FY2019 | Jun 30, 2018 | ($348.6K) | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | ($1.00M) | Sep 27, 2018 |
| FY2017 | Jun 30, 2016 | ($1.06M) | Sep 28, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.16M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $981.8K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $992.4K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $666.5K | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | $624.3K | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $886.1K | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $505.3K | Sep 24, 2020 |
| FY2019 | Jun 30, 2018 | $456.4K | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | $464.2K | Sep 27, 2018 |
| FY2017 | Jun 30, 2016 | $478.3K | Sep 28, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $7.80M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $7.54M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $7.38M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $5.61M | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | $3.71M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $3.90M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $2.10M | Sep 24, 2020 |
| FY2019 | Jun 30, 2018 | $1.37M | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | $1.31M | Sep 27, 2018 |
| FY2017 | Jun 30, 2016 | $1.55M | Sep 28, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($3.55M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($2.68M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($81.1K) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($933.4K) | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | $46.6K | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($592.5K) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($1.03M) | Sep 24, 2020 |
| FY2019 | Jun 30, 2018 | $100.7K | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | ($667.4K) | Sep 27, 2018 |
| FY2017 | Jun 30, 2016 | ($876.3K) | Sep 28, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $227.2K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $272.4K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $16.8K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $113.2K | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | $75.9K | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $119.2K | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $140.0K | Sep 24, 2020 |
| FY2019 | Jun 30, 2018 | $4.4K | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | $27.7K | Sep 27, 2018 |
| FY2017 | Jun 30, 2016 | $4.4K | Sep 28, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $19.79M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $16.91M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $19.74M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $16.70M | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | $6.26M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $6.35M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $7.49M | Sep 24, 2020 |
| FY2019 | Jun 30, 2018 | $2.51M | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | $1.80M | Sep 27, 2018 |
| FY2017 | Jun 30, 2016 | $2.12M | Sep 28, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $7.53M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $6.84M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $7.69M | Sep 30, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $12.26M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $10.07M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $12.05M | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | $8.97M | Sep 30, 2024 |
| FY2023 | Jun 30, 2021 | $3.43M | Sep 28, 2023 |
| FY2022 | Jun 30, 2020 | $2.77M | Sep 27, 2022 |
| FY2021 | Jun 30, 2019 | $3.38M | Sep 28, 2021 |
| FY2020 | Jun 30, 2018 | $564.0K | Sep 24, 2020 |
| FY2019 | Jun 30, 2017 | $558.4K | Sep 26, 2019 |
| FY2018 | Jun 30, 2016 | $587.2K | Sep 27, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $8.82M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $8.82M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $8.82M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $8.82M | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | $687.7K | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $687.7K | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $687.7K | Sep 24, 2020 |
| FY2019 | Jun 30, 2018 | $0 | Sep 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($56.97M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($51.19M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($48.24M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($48.09M) | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | ($47.17M) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($47.06M) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($45.64M) | Sep 24, 2020 |
| FY2019 | Jun 30, 2018 | ($45.02M) | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | ($44.67M) | Sep 27, 2018 |
| FY2017 | Jun 30, 2016 | ($43.66M) | Sep 28, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.77M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $405.3K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $2.93M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $605.7K | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | $861.7K | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $1.13M | Sep 28, 2021 |
| FY2021 | Jun 30, 2019 | $2.29M | Sep 28, 2021 |
| FY2020 | Jun 30, 2018 | $402.7K | Sep 24, 2020 |
| FY2019 | Jun 30, 2017 | $118.4K | Sep 26, 2019 |
| FY2018 | Jun 30, 2016 | $50.1K | Sep 27, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.93M | Sep 29, 2025 |
| FY2024 | Jun 30, 2024 | $2.21M | Sep 30, 2024 |
| FY2023 | Jun 30, 2023 | $2.73M | Sep 28, 2023 |
| FY2022 | Jun 30, 2022 | $2.35M | Sep 27, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Sep 27, 2022 |
| FY2019 | Jun 30, 2019 | 0 | Sep 26, 2019 |
| FY2019 | Jun 30, 2018 | 0 | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Sep 27, 2018 |
| FY2017 | Jun 30, 2016 | 0 | Sep 28, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Sep 28, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Sep 27, 2022 |
| FY2019 | Jun 30, 2019 | 0 | Sep 26, 2019 |
| FY2019 | Jun 30, 2018 | 0 | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Sep 27, 2018 |
| FY2017 | Jun 30, 2016 | 0 | Sep 28, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Sep 28, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 7.71M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 6.07M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 6.07M | Sep 30, 2024 |
| FY2024 | Nov 1, 2022 | 5.64M | Sep 30, 2024 |
| FY2024 | Oct 31, 2022 | 16.92M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 5.64M | Sep 28, 2023 |
| FY2022 | Jun 30, 2021 | 13.28M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | 13.19M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | 12.07M | Sep 24, 2020 |
| FY2019 | Jun 30, 2018 | 10.20M | Sep 26, 2019 |